U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Metastatic Esophageal Squamous Cell Carcinoma

MedGen UID:
222971
•Concept ID:
C1142025
•
Neoplastic Process

Definition

A squamous cell carcinoma that arises from the esophagus and has metastasized to another anatomic site. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMetastatic Esophageal Squamous Cell Carcinoma

Professional guidelines

PubMed

Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Fang R, Wang S, Liu Y, Xu J
Adv Ther 2023 Mar;40(3):1019-1030. Epub 2023 Jan 9 doi: 10.1007/s12325-022-02402-z. PMID: 36622553
Cost-effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more.
Song X, Zheng Z, Li X, Cai H, Zhang L
J Comp Eff Res 2022 Apr;11(6):391-397. Epub 2022 Feb 18 doi: 10.2217/cer-2021-0112. PMID: 35179053
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Abraham P, Gricar J, Zhang Y, Shankaran V
Adv Ther 2020 Jul;37(7):3392-3403. Epub 2020 Jun 12 doi: 10.1007/s12325-020-01394-y. PMID: 32533533Free PMC Article

Recent clinical studies

Etiology

Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial.
He M, Wang Z, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Sheng Z, Zeng W, Song L, Xu RH, Luo H
Med 2024 Sep 13;5(9):1137-1149.e3. Epub 2024 Jun 12 doi: 10.1016/j.medj.2024.05.008. PMID: 38870932
Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY, Ko JMY, Lam KO, Kwong DLW, Lo AWI, Wong IYH, Wong CLY, Chan SY, Chan KK, Law TT, Dai W, Fong HCH, Choy FSF, Lo CK, Chen C, Law SYK, Lung ML
JAMA Surg 2023 Nov 1;158(11):1141-1150. doi: 10.1001/jamasurg.2023.4395. PMID: 37728901Free PMC Article
Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma.
Ahn D, Sidel M, Panattoni L, Sacks N, Hernandez J, Villacorta R
Future Oncol 2022 Sep;18(30):3419-3433. Epub 2022 Sep 13 doi: 10.2217/fon-2022-0708. PMID: 36098270
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, Gu K, Tao M, Wang X, Cui C, Xu N, Xiao J, Gao Q, Liu Y, Zhang T, Bai Y, Li W, Zhang Y, Dai G, Ma D, Zhang J, Bai C, Huang Y, Liao W, Wu L, Chen X, Yang Y, Wang J, Ji S, Zhou H, Wang Y, Ma Z, Wang Y, Peng B, Sun J, Mancao C
Nat Commun 2022 Feb 14;13(1):857. doi: 10.1038/s41467-022-28408-3. PMID: 35165274Free PMC Article
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH; ESCORT-1st Investigators
JAMA 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836. PMID: 34519801Free PMC Article

Diagnosis

First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.
Zheng Z, Chen H, Cai H, Zhu H
Expert Rev Pharmacoecon Outcomes Res 2024 Mar;24(3):397-404. Epub 2023 Dec 6 doi: 10.1080/14737167.2023.2290609. PMID: 38031985
Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions.
Jiang M, Hu Y, Lin G, Chen C, Li H
Front Immunol 2023;14:1177085. Epub 2023 May 30 doi: 10.3389/fimmu.2023.1177085. PMID: 37325652Free PMC Article
Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Fang R, Wang S, Liu Y, Xu J
Adv Ther 2023 Mar;40(3):1019-1030. Epub 2023 Jan 9 doi: 10.1007/s12325-022-02402-z. PMID: 36622553
Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.
Danese M, Gricar J, Abraham P
Future Oncol 2022 Mar;18(8):927-936. Epub 2022 Jan 27 doi: 10.2217/fon-2021-0460. PMID: 35081734
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.
Kotecki N, Hiret S, Etienne PL, Penel N, Tresch E, François E, Galais MP, Ben Abdelghani M, Michel P, Dahan L, Ghiringelli F, Bedenne L, Samalin E, Piessen G, Bennouna J, Peugniez C, El Hajbi F, Clisant S, Kramar A, Mariette C, Adenis A
Oncology 2016;90(2):88-96. Epub 2016 Jan 20 doi: 10.1159/000442947. PMID: 26784946

Therapy

Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study.
Park S, Lee Y, Lee J, Min YW, Kim HK, Choi JY, Jung HA, Choi YS, Choi YL, Shim YM, Sun JM
Cancer Res Treat 2024 Apr;56(2):567-579. Epub 2023 Oct 16 doi: 10.4143/crt.2023.897. PMID: 37846467Free PMC Article
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E; RATIONALE-302 Investigators
J Clin Oncol 2022 Sep 10;40(26):3065-3076. Epub 2022 Apr 20 doi: 10.1200/JCO.21.01926. PMID: 35442766Free PMC Article
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, Gu K, Tao M, Wang X, Cui C, Xu N, Xiao J, Gao Q, Liu Y, Zhang T, Bai Y, Li W, Zhang Y, Dai G, Ma D, Zhang J, Bai C, Huang Y, Liao W, Wu L, Chen X, Yang Y, Wang J, Ji S, Zhou H, Wang Y, Ma Z, Wang Y, Peng B, Sun J, Mancao C
Nat Commun 2022 Feb 14;13(1):857. doi: 10.1038/s41467-022-28408-3. PMID: 35165274Free PMC Article
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators
N Engl J Med 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380. PMID: 35108470
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH; ESCORT-1st Investigators
JAMA 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836. PMID: 34519801Free PMC Article

Prognosis

Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Ikeda G, Miyakoshi J, Yamamoto S, Kato K
Future Oncol 2024 Apr;20(11):665-677. Epub 2023 Dec 21 doi: 10.2217/fon-2022-1092. PMID: 38126175
Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study.
Park S, Lee Y, Lee J, Min YW, Kim HK, Choi JY, Jung HA, Choi YS, Choi YL, Shim YM, Sun JM
Cancer Res Treat 2024 Apr;56(2):567-579. Epub 2023 Oct 16 doi: 10.4143/crt.2023.897. PMID: 37846467Free PMC Article
Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY, Ko JMY, Lam KO, Kwong DLW, Lo AWI, Wong IYH, Wong CLY, Chan SY, Chan KK, Law TT, Dai W, Fong HCH, Choy FSF, Lo CK, Chen C, Law SYK, Lung ML
JAMA Surg 2023 Nov 1;158(11):1141-1150. doi: 10.1001/jamasurg.2023.4395. PMID: 37728901Free PMC Article
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E; RATIONALE-302 Investigators
J Clin Oncol 2022 Sep 10;40(26):3065-3076. Epub 2022 Apr 20 doi: 10.1200/JCO.21.01926. PMID: 35442766Free PMC Article
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH; ESCORT-1st Investigators
JAMA 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836. PMID: 34519801Free PMC Article

Clinical prediction guides

Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial.
He M, Wang Z, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Sheng Z, Zeng W, Song L, Xu RH, Luo H
Med 2024 Sep 13;5(9):1137-1149.e3. Epub 2024 Jun 12 doi: 10.1016/j.medj.2024.05.008. PMID: 38870932
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.
Ajani J, El Hajbi F, Cunningham D, Alsina M, Thuss-Patience P, Scagliotti GV, Van den Eynde M, Kim SB, Kato K, Shen L, Li L, Ding N, Shi J, Barnes G, Van Cutsem E
ESMO Open 2024 Jan;9(1):102202. Epub 2023 Dec 19 doi: 10.1016/j.esmoop.2023.102202. PMID: 38118368Free PMC Article
Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study.
Park S, Lee Y, Lee J, Min YW, Kim HK, Choi JY, Jung HA, Choi YS, Choi YL, Shim YM, Sun JM
Cancer Res Treat 2024 Apr;56(2):567-579. Epub 2023 Oct 16 doi: 10.4143/crt.2023.897. PMID: 37846467Free PMC Article
Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients.
Kim SB, Van Cutsem E, Ajani J, Shen L, Barnes G, Ding N, Tao A, Xia T, Zhan L, Kato K
Curr Med Res Opin 2024 Jan;40(1):69-75. Epub 2024 Jan 3 doi: 10.1080/03007995.2023.2270894. PMID: 37846080
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E; RATIONALE-302 Investigators
J Clin Oncol 2022 Sep 10;40(26):3065-3076. Epub 2022 Apr 20 doi: 10.1200/JCO.21.01926. PMID: 35442766Free PMC Article

Recent systematic reviews

Outcomes and Prognostic Factors of Patients with Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Undergoing Immunotherapy- Versus Chemotherapy-Based Regimens: Systematic Review and Pooled Analyses.
Colloca GA, Venturino A
J Gastrointest Cancer 2024 Dec;55(4):1541-1550. Epub 2024 Aug 17 doi: 10.1007/s12029-024-01100-z. PMID: 39153173
Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
Gao TT, Shan JH, Yang YX, Zhang ZW, Liu SL, Xi M, Liu MZ, Zhao L
BMC Cancer 2022 Sep 17;22(1):992. doi: 10.1186/s12885-022-10086-5. PMID: 36115960Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...